Tag Archives: roots analysis

The pharmaceutical secondary packaging market

Roots Analysis has announced the addition of “Pharmaceutical Secondary Packaging Market” report to its list of offerings.rnrnThe anticipated growth in the therapeutics pipeline is likely to translate into a significant rise in the demand for cost-effective and quality secondary packaging solutions, presenting lucrative opportunities for contract packaging organizations. Driven by the growth of the overall pharmaceutical industry and increasing preference of drug developers for outsourcing certain operations, the secondary packaging providers market is expected to witness a steady increase. rnrnTo order this 210+ page report, which features 130+ figures and 160+ tables, please visit rnhttps://www.rootsanalysis.com/reports/pharmaceutical-secondary-packaging-market.html rnrnKey Market Insights rnrnAround 165 companies claim to offer pharmaceutical secondary packaging services, globallyrnMajority (51%) of the industry stakeholders are headquartered in Europe, followed by those based in North America (37%) and Asia-Pacific (12%). In addition, close to 65% of the secondary packaging providers offer cartons, followed by companies offering boxes (53%) and other packaging formats, such as trays and pouches (29%).rnrnPartnership activity has grown at an annualized rate of ~85%, between 2018-2021rnMaximum number of partnerships were observed in 2020 (29), indicating a recent increase in the partnership activity in this domain. Majority of these agreements were reported to be instances of acquisitions, representing over 45% of the total number of instances.rnrnExpansion activity in this domain has grown at a CAGR of ~55%, between 2018 and 2022 rnMost of such initiatives were focused on expanding the existing capacity (40%), followed by instances of establishing a new facility (38%) and facility expansions (13%). Further, majority of the investments were made in facilities located in North America (54%) and Europe (35%). rnrnrnTo request a sample copy / brochure of this report, please visit rnhttps://www.rootsanalysis.com/reports/pharmaceutical-secondary-packaging-market.htmlrnrnKey Questions Answeredrn Who are the leading players engaged in the pharmaceutical secondary packaging domain?rn What is the relative competitiveness of pharmaceutical secondary packaging providers?rn Which types of partnership models are most commonly adopted by industry stakeholders?rn What kind of expansion initiatives have been undertaken by pharmaceutical secondary packaging providers?rn How is the current and future market opportunity likely to be distributed across key market segments?rnrnThe financial opportunity within the pharmaceutical secondary packaging market has been analyzed across the following segments:rn Type of Secondary Packagingrn Boxesrn Cartonsrn Pouchesrnrn Type of Primary Packaging Packedrn Ampoulesrn Blister Packsrn Bottlesrn Cartridgesrn Syringesrn Vialsrnrn Key Geographical Regions rn North Americarn Europern Asia-Pacificrn MENArn Latin Americarn Rest of the World rnrnThe report also features inputs from eminent industry stakeholders, according to whom, the increasing pharmaceutical pipeline and high demand for life-saving drugs will drive the growth of the pharmaceutical secondary packaging providers, in the coming future. The report includes detailed transcripts of discussions held with the following experts:rn Jake Aspinall (Commercial Director, Active Pharma Supplies)rn Silvio Del Deo (Managing Director, Depo Pack)rn Joe Luke (Vice President, Sales and Marketing, Reed-Lane)rnrnThe research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its pharmaceutical secondary packaging offerings, recent developments and an informed future outlook.rn Catalentrn Patheon (By Thermo Fisher Scientific)rn PCI Pharma Services rn Pfizer CentreOnern Sharprn Almac Group rn Central Pharma rn CordenPharma rn Eurofins CDMO rn Tjoapack rn ABS (Australian Blister Sealing)rn Bushu Pharma rn CMIC rn Kishore group rn Prince Art Packages rnrnFor additional details, please visit rnhttps://www.rootsanalysis.com/reports/pharmaceutical-secondary-packaging-market.htmlrnor email [email protected] rnrnYou may also be interested in the following titles: rn1. Biopharmaceutical Excipient Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035rn2. Continuous Manufacturing (Small Molecules and Biologics) Market (2nd Edition): Industry Trends and Global Forecasts, 2022-2035rn3. Container Closure Integrity Testing Services Market: Industry Trends and Global Forecasts, 2022-2035rnrnContact:rnBen Johnsonrn+1 (415) 800 3415rn+44 (122) 391 [email protected] – https://www.facebook.com/RootsAnalysisrnLinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/rnTwitter – https://twitter.com/RootsAnalysisrnMedium – https://medium.com/@RootsAnalysisrnPinterest – https://in.pinterest.com/RootsanalysisPin/_saved/rnQuora – https://rootsanalysisinsights.quora.com/rn https://www.rootsanalysis.com/reports/pharmaceutical-secondary-packaging-market.html

The contract regulatory affairs-management services market for medical

Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CROs Market, 2019-2030.” rnrnThe report features a detailed study on the current landscape of contract service providers focused on regulatory affairs management for medical devices. The study features an in-depth analysis, highlighting the capabilities of the various CROs engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:rn A detailed review of the current Medical Device CRO market landscape of the medical devices regulatory affairs outsourcing market, featuring a list of over 400 CROs engaged in this domain.rn A detailed discussion on the need for regulatory review / oversight across different stages of the medical devices supply chain, with emphasis on the optimization of the supply chain using upcoming tools / technologies.rn An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America, Europe, Asia-Pacific and rest of the world.rn An elaborate discussion on the various outsourcing business models adopted for regulatory affairs management, along with an insightful Harvey ball analysis of key considerations that need to be assessed by industry stakeholders while selecting a CRO partner.rn An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers that are active in the domain, based on information gathered via secondary research (for top-ten medical device players) and primary research.rn A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing regulatory affairs management services to medical device developers.rnrnFor more information please click on the following linkrnhttps://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html rnrnOther Recent Offeringsrn1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 rn2. Medical Device Labels Manufacturing Market, 2019-2030rn3. Medical Device Contract Manufacturing Market, 2019-2030rnrnAbout Roots AnalysisrnRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] InformationrnRoots Analysis Private LimitedrnBen Johnson rn+1 (415) 800 [email protected] – https://www.facebook.com/RootsAnalysisrnLinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/rnTwitter – https://twitter.com/RootsAnalysisrnMedium – https://medium.com/@RootsAnalysisrnPinterest – https://in.pinterest.com/RootsanalysisPin/_saved/rnQuora – https://rootsanalysisinsights.quora.com/rn rn https://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html

NOVEL OCULAR DRUG DELIVERY MARKET – GROWING INTEREST IN THE PHARMACEUTICAL INDUSTRY AND THE GROWING FUTURE POTENTIAL

The Novel Ocular Drug Delivery Devices Market report features an extensive study of the current market landscape and the likely adoption of novel ocular drug delivery devices, over the next decade. The study features a detailed analysis of the key drivers and trends related to this evolving domain.rnrnAccording to the World Health Organization (WHO), more than 2.2 billion individuals across the world suffer from some degree of vision impairment caused due to various ophthalmic disorders, such as glaucoma, trachoma, cataract, diabetic retinopathy and wet age-related macular degeneration. Around 50% of the cases are left either unaddressed and / or could have been prevented. It is also worth highlighting that around 1.7 billion individuals worldwide are expected to lose their vision by 2050. Studies suggest that, if administered with the help of topical eye drops, around 95% of the drug is lost due to a number of challenges, such as dilution of product by tears and permeation issues related to cornea. Therefore, drug delivery formulations, such as eye drops and ointments, cannot be considered as an optimal treatment option for vision-threatening diseases. rnrnTo request a sample report: https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market/request-sample.htmlrnOwing to the concerns, there is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. Over time, several pharmaceutical companies across the world have undertaken various initiatives to develop novel drug delivery devices, such as sustained release implants, ocular inserts and punctal plugs, that are capable of enabling effective administration of drugs, while overcoming the existing challenges. rnrnTo order customize report: https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market/request-customization.htmlrnrnBased on the type of ocular disorders, therapeutics can be delivered into the ocular regions. The selection of appropriate route of administration for a particular drug, depends on the target ocular tissue. rnrnFor more information, please click on the following link:rnhttps://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market.htmlrnrnYou may also be interested in the following reports:rn1. Container Closure Integrity Testing Services Marketrn2. Global Autoinjectors Market rn3. Large Volume Wearable Injectors Marketrn4. At-Home Blood Collection and Micro Sampling Devices MarketrnrnrnAbout Roots AnalysisrnRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] InformationrnRoots Analysis Private LimitedrnBen Johnson rn+1 (415) 800 [email protected] – https://www.facebook.com/RootsAnalysisrnLinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/rnTwitter – https://twitter.com/RootsAnalysisrnMedium – https://medium.com/@RootsAnalysisrnPinterest – https://in.pinterest.com/RootsanalysisPin/_saved/rn https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market/request-sample.html

THE REMOTE PATIENT MONITORING MARKET IS ANTICIPATED TO WITNESS SIGNIFICANT GROWTH OVER THE NEXT DECADE

The ability to remotely monitor patients using various consultation tools and software have revolutionized modern healthcare practices. The concept of monitoring patients over telephone can be traced back to the 1800’s. However, it was not until 1961, during the National Aeronautics and Space Administration (NASA) space mission, when remote physiologic monitoring of astronauts was efficiently required. Further, with the introduction of cloud computing in 1960s, the remote patient monitoring domain evolved at a significant pace, as these solutions were capable of enabling information sharing and analysis to carry out the process in a more robust manner. Since then, the domain has gained more popularity amongst patients and their caregivers owing to ease of use and cost-effectiveness.rnrnTo request a sample report: https://www.rootsanalysis.com/reports/telemedicine-tools-and-software-providers-market/request-sample.htmlrnrnIt worth highlighting that despite the various advantages offered, it was not until the COVID-19 pandemic that remote patient monitoring (RPM) solutions witnessed rapid adoption. During the pandemic, several regional governments endorsed the use of such solutions in order reduce low-importance or follow-up visits to hospitals and clinics and consequently, limit the spread of the virus. Further, various healthcare facilities, such as hospitals and clinics, have actively started monitoring and managing their patients remotely. At present, RPM solutions are complimenting conventional approaches to provide better and well-defined healthcare facilities to patients.rnrnRPM solutions can facilitate services for patients suffering from chronic, as well as acute, disorders. As a result, RPM solutions are capable of reducing the burden on healthcare facilities, especially in the wake of a pandemic. It is worth highlighting that RPM solutions involve a set of functions that are performed by the software to produce the analyzed output. These functions include data collection, transmission, evaluation and notifications. rnrnTo order customize report: https://www.rootsanalysis.com/reports/telemedicine-tools-and-software-providers-market/request-customization.htmlrnrn Data Collection: It includes continuous collection of a patient’s vital signs from various sources, such as wearable devices, IoT devices and sensors. It is important to mention that the data is collected remotely, without an oversight from a healthcare provider. rn Transmission: The data collected from RPM devices is transmitted to the healthcare provider via the internet, text, phone or other modes of communication. The collated data can either be transmitted continuously or stored in a cloud / web-based platform. rn Evaluation: The transmitted data is then analyzed by a software in order to evaluate the patient’s condition. The physician then examines the received data and provides information on areas of concern. rn Notification: The data gathered is then fed into an AI system that sends quick alerts to the patient. In case immediate attention is required, alerts are sent to the specific emergency responders in order to prioritize the treatment. In addition to risk-alerts, the physicians might communicate relevant data-driven insights and interventions to patients. rnrnrnFor more information, please click on the following link:rnhttps://www.rootsanalysis.com/reports/telemedicine-tools-and-software-providers-market.htmlrnrnrnYou may also be interested in the following reports:rn1. Antibody Drug Conjugates Marketrn2. Cell and Gene Therapy CROs Market rn3. Bispecific Antibody Therapeutics Market rn4. Genome Editing Services Market rnrnrnAbout Roots AnalysisrnRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] InformationrnRoots Analysis Private LimitedrnBen Johnson rn+1 (415) 800 [email protected] – https://www.facebook.com/RootsAnalysisrnLinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/rnTwitter – https://twitter.com/RootsAnalysisrnMedium – https://medium.com/@RootsAnalysisrnPinterest – https://in.pinterest.com/RootsanalysisPin/_saved/rnQuora – https://rootsanalysisinsights.quora.com/rnrn https://www.rootsanalysis.com/reports/telemedicine-tools-and-software-providers-market/request-sample.html

The squamous non-small cell lung cancer market

Roots Analysis has announced the addition of “Squamous Non-small Cell Lung Cancer Market, 2021-2031” report to its list of offerings.rnrnSuccess of approved squamous non-small cell lung cancer therapies, such as Keytruda®, Opdivo® and Portrazza®, has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of these therapies to effectively treat NSCLC, an aggressive form of lung carcinoma, justifies its potential as a promising disease management recourse. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives. rnrnTo order this 122+ page report, which features 81+ figures, please visit https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.htmlrnrnKey Market InsightsrnrnMore than 85 product candidates are being investigated to treat metastatic or advanced squamous NSCLC patients rnMore than 78% of the therapies are being evaluated in early stages, either as monotherapies or in combination with other products. Further, majority of these therapies (45%) are designed for administration via the intravenous route. It is worth highlighting that, till date, five biologics and one small molecule have been approved for the treatment of squamous NSCLC.rnrnSeveral big pharma players have an advanced pipeline of drugs targeting squamous NSCLC rnOver 34 companies engaged in this domain represent large / very large businesses. Although biologics emerged as the most prominent type of molecule in the overall pipeline, big pharma players were observed to prefer developing small molecules against lung carcinomas. Interestingly, 53% of such firms are based in North America.rnrnTo request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market/request-sample.htmlrnrnKey Questions Answeredrn What are the prevalent R&D trends related to squamous non-small cell lung cancer?rn What are the key challenges faced by stakeholders engaged in this domain?rn What are the principal therapies being developed by the industry players?rn Who are the leading industry and non-industry players in this market?rn What are the contributions of big pharma players in this field?rn What are the key geographies where research on squamous non-small cell lung cancer is being conducted?rn Who are the key investors in this domain? rn Who are the key opinion leaders / experts in this field?rn What kind of partnership models are commonly adopted by industry stakeholders? rn What are the factors that are likely to influence the evolution of this upcoming market?rnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnFor additional details, please visit rnhttps://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html or email [email protected] rnrnYou may also be interested in the following titles: rn1. RAS Targeting Therapies Market, 2021-2031rn2. Novel T-Cell Immunotherapies Market, 2021-2030rn3. HER2 Targeting Therapies Market, 2021-2030rnrnContact:rnBen Johnsonrn+1 (415) 800 3415rn+44 (122) 391 [email protected] rn https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html

The site management organizations (SMO) market

The Site Management Organizations Market report features an extensive study of the current market landscape and future potential of the site management organizations market. rnrnRoots Analysis has announced the addition of “Site Management Organizations (SMO) Market, 2021 – 2035” report to its list of offeringsrnrnIn recent years, drug / device developers have demonstrated a preference to continue relying on SMOs for conducting clinical trials in order to significantly optimize trial cost and research timelines. Driven by the steady growth in clinical research activity and inherent benefits offered by SMOs, the market opportunity for such players is projected to grow at a significant pace in the foreseen future.rnrnTo order this 270+ page report, which features 95+ figures and 120+ tables, please visit rnhttps://www.rootsanalysis.com/reports/site-management-organizations-market.html rnrnKey Market Insights rnrnAround 250 companies across the world claim to offer clinical trial site management services rnMajority (43%) of the industry stakeholders are headquartered in North America, followed by those based in Asia-Pacific (32%) and Europe (19%). In addition, 25% of the companies engaged in this domain offer site management services across the globe, followed by those providing services in Asia-Pacific (23%).rnrn200+ partnerships were established in this domain, during the period 2016-2021rnService alliances (26%) and clinical trial agreements (23%) emerged as the most common types of partnership models adopted by stakeholders engaged in this domain. Nearly 65% of the deals in this domain were established after 2018, with the maximum activity being reported in 2021 (56). rnrn~USD 1 billion invested in various domain focused initiatives, since 2015 rnMaximum number of funding instances (21%) were reported in 2021, amounting to USD 614 million in capital investments. A significant number of funding instances (43%) were venture capital rounds, followed by instances of other equity (29%) and grants (7%). rnrnrnTo request a sample copy / brochure of this report, please visit rnhttps://www.rootsanalysis.com/reports/site-management-organizations-market.htmlrnrnKey Questions Answeredrn Who are the leading players engaged in the clinical trial site management domain?rn What is the relative competitiveness of different site management organizations?rn What type of partnership models are commonly adopted by stakeholders in this industry?rn What is the capital investments trend in the site management organizations domain?rn Which are the most active clinical trial centers?rn What are the major market trends and driving factors that are likely to impact the growth of site management organizations market?rn How is the current and future market opportunity likely to be distributed across key market segments?rnrnThe report also features inputs from eminent industry stakeholders, according to whom, complexities associated with clinical trial processes and increasing clinical pipeline will drive the growth of the third-party service providers, such as SMOs, engaged in this domain, in the coming future. The report includes detailed transcripts of discussions held with the following experts:rn Vinod Gyanchandani (Country Head – Clinical Operations, GDD Experts)rn Marisa Vico (Medical Director and Operations Manager, SMO – Dra. Marisa Vico)rn Eugene Winifred (Project Manager, Syncretic Clinical Research Services)rnrnrnFor additional details, please visit rnhttps://www.rootsanalysis.com/reports/site-management-organizations-market.htmlrnor email [email protected] rnrnYou may also be interested in the following titles: rn1. Patient Recruitment and Retention Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030rn2. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030rn3. Clinical Trial Planning and Design Services Market: Industry Trends and Global Forecasts, 2021-2030rn4. Biospecimen Contract Research Services Market: Industry Trends and Global Forecast, 2021-2030rn5. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030rnrnAbout Roots AnalysisrnRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] InformationrnRoots Analysis Private LimitedrnBen Johnsonrn+1 (415) 800 3415rn+44 (122) 391 [email protected] https://www.rootsanalysis.com/reports/site-management-organizations-market.html

REMOTE PATIENT MONITORING TOOLS AND SOFTWARE: OVERALL MARKET LANDSCAPE

During our study, we were able to identify over 200 remote patient monitoring (RPM) tools and software. It is worth mentioning, the RPM tools and software market is dominated by the presence of small companies (57%), followed by mid-sized players (23%). This can be attributed to the fact that healthcare domain has seen a shift from traditional medicines to telehealth solutions in the recent years, especially with increase in cases where the patients are not able to frequently visit their healthcare professional. In fact, in the recent years, a number of RPM solutions have received regulatory approval, which has spurred the establishment of many start-ups in this domain.rnrnFor more information, please click on the following link https://www.rootsanalysis.com/reports/telemedicine-tools-and-software-providers-market.htmlrnrnIn fact, most of the players engaged in this domain were established between 2011 and 2015. Further, in recent years, more than 35 RPM solution providers have been established, indicating a growing demand for RPM solutions. Notable examples include (established before 1950; in reverse chronological order) Abbott (1888), Dräger Medical (1889), Kaiser Permanente (1945), Medtronic (1949), Murata Vios (1944), OMRON Healthcare (1933), Siemens Healthineers (1847), and Smiths Medical (1940). rnrnDuring our research, we were able to identify that most of the solutions are currently made available / being developed in the form of software as a service (108). Notable examples include (established since 2019; in alphabetically order) Caregility.com (2019), Diagnext (2019), Doccla (2019), Doconvid (2020), Kayan Health (2019) and PurpleRibbon Healthcare Services (2020).rnrnCurrently, around 70 RPM solutions have been approved in various countries. Of these, majority of the solution have been approved in US (79%), followed by solutions that have been approved in Germany (14%). rnrnEven though efforts for development of RPM solutions have been undertaken by players based all across the globe, majority of the developers (63%) are headquartered in North America. It is worth mentioning that within North America, maximum number of players are headquartered in the US (98%). This trend is followed by companies headquartered in Asia-Pacific (21%).rnrnIn order to determine the relative competitiveness of remote patient monitoring software, we focused on several relevant parameters, such as, such as supplier power (in terms of expertise of the developer) and key product-related specifications (such as status of development, HIPPA compliance, type of software, area(s) of application, therapeutic area, purpose of software, number of patient monitoring related service(s) offered, type of telemedicine operation, and type of business model).rnrnAdditionally, the insights on company competitiveness have been presented in the form of a 2*2 matrix, with the company’s experience (abscissa) on the x-axis and competitiveness (ordinate) on the y-axis. rnrnAs per our proprietary scoring criteria, software as a service RPM solution in this domain, software 2B emerged as the most prominent player based on product competitiveness. It is worth mentioning that this product is HIPAA compliant and used for commercial purposes. Further, it has a wide range of applications, such as blood pressure measurement, oxygen saturation detection and body temperature analysis. It was followed by Promantra RPMPro (offered by Promantra Synergy Solutions), software 1B (offered by company 1) and software 3A (offered by company 3).rnTo Request Sample Page https://www.rootsanalysis.com/reports/telemedicine-tools-and-software-providers-market/request-sample.htmlrnrnrnAbout Roots AnalysisrnRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] InformationrnRoots Analysis Private LimitedrnGaurav Chaudharyrn+1 (415) 800 [email protected] – https://www.facebook.com/RootsAnalysisrnLinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/rnTwitter – https://twitter.com/RootsAnalysisrnMedium – https://medium.com/@RootsAnalysisrnPinterest – https://in.pinterest.com/RootsanalysisPin/_saved/rnQuora – https://rootsanalysisinsights.quora.com/rnrnrn https://www.rootsanalysis.com/reports/til-therapies-market.html

TIL-BASED THERAPIES DEVELOPERS, ACROSS DIFFERENT REGIONS

Several academic groups, including various universities and hospitals, are contributing significantly towards the development of these novel therapeutics against various oncological disorders. Eminent researchers and experienced scientists, affiliated to such renowned research / academic institutes, are generally chosen to lead clinical investigations for specific disease areas. Various principal investigators or sub-investigators or study directors of clinical trials, considering them to be the key opinion leaders (KOLs), who are actively involved in the study of TIL-based trials worldwide.rnrnTIL-based therapies are currently being developed by various research groups at (in alphabetical order) Duke University Medical Center, H. Lee Moffitt Cancer Center and Research Institute, Hillman Cancer Center, Keio University School of Medicine, Lausanne University Hospital, MD Anderson Cancer Center, Nantes University Hospital, National Cancer Institute, Ohio State University Comprehensive Cancer Center and Roswell Park Cancer Institute. rnrnFor more information, please click on the following link https://www.rootsanalysis.com/reports/til-therapies-market.htmlrn https://www.rootsanalysis.com/reports/telemedicine-tools-and-software-providers-market.html

PRE-STERILIZED / READY-TO-USE PRIMARY PACKAGING MARKET – CURRENT MARKET LANDSCAPE

Presently, more than 150 pre-sterilized / RTU primary packaging systems, including cartridges, syringes and vials, as well as their respective closure systems are available worldwide. Majority (50%) of the pre-sterilized / RTU primary packaging systems are closures, followed by containers (34%) and container-closure systems (16%). It is worth highlighting that, of the total, 54 closures are suitable for use with vials, 19 are suitable for use with syringes and the remaining 5 are compatible with cartridges.rnrnAmongst the primary packaging containers, vials and syringes emerged as the most common types of pre-sterilized / RTU containers manufactured by stakeholders engaged in this domain. This can be attributed to the fact that these containers are the most suitable for packaging of small volume of therapeutics, such as biologics, cell therapies, small molecules, vaccines and other potent products.rnrnTo order this report, please visit https://www.rootsanalysis.com/reports/view_document/pre-sterilized-ready-to-use-primary-packaging-market/224.htmlrnrnFurther, glass emerged as the most preferred fabrication material used for pre-sterilized / RTU containers. Of these, majority (83%) of the containers are made of type I borosilicate glass, followed by those fabricated using type II treated soda-lime glass (10%) and type III soda-lime glass (7%). This is followed by pre-sterilized / RTU containers fabricated using plastic (29%), primarily cyclic olefin polymer. Examples include (in alphabetical order) ClearVial (MedicoPack), Daikyo Crystal Zenith Insert Needle Syringe Systems (Daikyo Seiko), Daikyo Crystal Zenith Ready to Use Vials (Daikyo Seiko) and SCHOTT TopPac sensitive (SCHOTT).rnrnSterilization of primary packaging systems is considered to be an essential step in the overall healthcare manufacturing process as it deactivates various forms of contaminating agents (particularly referring to bacteria, fungi, protozoa and viruses). Majority (43%) of the pre-sterilized / RTU containers are sterilized using ethylene oxide, followed by those employing steam sterilization (34%).rnrnPresently, close to 50 companies claim to be actively involved in the manufacturing of pre-sterilized / RTU primary packaging systems. The market landscape is highly fragmented, featuring a mix of small (less than 50 employees, 17%), mid-sized (51-500 employees, 37%), large (501-1,000 employees, 2%) and very large (more than 1,000 employees, 44%) companies. The pre-sterilized / RTU packaging manufacturers market is fragmented, featuring the presence of established players as well as new entrants, which are well distributed across different geographical regions. Examples of established players include (in decreasing order of experience) Gerresheimer (1864), Sartorius (1870), SCHOTT (1884), DWK Life Sciences (1887), SGD Pharma (1896) and Becton, Dickinson and Company (1897). rnrnAbout Roots AnalysisrnRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] InformationrnRoots Analysis Private LimitedrnGaurav Chaudharyrn+1 (415) 800 [email protected] https://www.rootsanalysis.com/reports/view_document/pre-sterilized-ready-to-use-primary-packaging-market/224.html

The modular facilities market is estimated to be worth USD 6.4 billion in 2030, predicts Roots Analysis

Roots Analysis is pleased to announce the publication of its recent study, titled, “Modular Facilities in Pharmaceutical and Biotechnology Market”rnrnThe report features an extensive study of the current market landscape and future potential of the players engaged in offering services for modular facility construction for biotechnology and pharmaceutical industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:rnrn An in-depth review of the market landscape of players that offer services for modular facility construction for biotechnology and pharmaceutical industries, along with the details of certifications obtained and COVID-19 related initiatives undertaken by modular service providers.rn A review of the market landscape of modular cleanrooms along with information on their year of establishment, company size, location of headquarters, type of industry served, type of modular cleanrooms, type of modular cleanroom components. It also includes details related to regulatory approvals and certifications.rn An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021.rn An in-depth analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility. rn An insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players.rn Elaborate profiles of key players that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries. rn An in-depth review of emerging trends, including processing technologies with modular facilities, the shift towards smaller, multi-purpose modular facilities, and technological advancements in modular construction processes.rn A detailed discussion on the various growth drivers and trends related to modular solutions in emerging markets by pharmaceutical / biopharmaceutical CMOs.rn A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)rnrnTo Request Sample Page – https://www.rootsanalysis.com/reports/178/request-sample.htmlrnrnDownload Free Insights now – https://www.rootsanalysis.com/reports/178/free-insights.htmlrnrnTranscripts of interviews held with the following senior level representatives of stakeholder companiesrnAlan de Zayas (Modular Building Manufacturing and Construction Team, Avon Modular Construction)rn François Abiven (Executive Vice-President Global Business Unit BLS and Luca Mussati Vice President, Pharma and Biotech Life Sciences, Exyte)rn Maik Jornitz (President and Chief Executive Officer, G-CON Manufacturing)rn Pär Almhem (President, Modwave)rn Sulogna Roy (Ex Sales Manager, Zeton)rn Vernon Solomon (Specialist in Modular Design for Cleanrooms and Close Tolerance Temperature and Humidity Control, Environmental Systems Corporation)rnrnKey companies covered in the reportrn Cytivarn G-CON Manufacturingrn Pharmadule Morimatsurn NNErn IPM Technologiesrn KeyPlantsrn Germfree Laboratoriesrn ModuleCO PharmarnrnFor more information, please click on the following linkrnhttps://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.htmlrnrnYou may also be interested in the following titles: rn1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030rn2. Biopharmaceutical CROs Market, 2021-2030rn3. Continuous Manufacturing Equipment Providers Market, 2021-2030rn4. DNA-Encoded Libraries: Platforms and Services Marketrn5. Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028rnrnrnAbout Roots AnalysisrnRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] InformationrnRoots Analysis Private LimitedrnGaurav Chaudharyrn+1 (415) 800 [email protected] https://www.rootsanalysis.com/reports/view_document/modular-manufacturing-market/178.html#overview